Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 0 study of KAND 567 inpatients with lymphoma

Trial Profile

A phase 0 study of KAND 567 inpatients with lymphoma

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 07 Dec 2018

At a glance

  • Drugs KAND-567 (Primary)
  • Indications Lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Dec 2018 New trial record
    • 23 Nov 2018 According to a Kancera media release, the company is conducting this phase 0 study in collaboration with Karolinska Hospital and the Institute.
    • 23 Nov 2018 According to a Kancera media release, the company expects to complete the enrollment in this study in Dec 2018 and the analysis are expected to complete in Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top